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Background: Current screening recommendations for early detection of lithium-associated hyperparathyroidism
propose an exclusive measurement of serum albumin-adjusted calcium (Aac) concentration as a single first step.
However, longitudinal data in patients with recurrent affective disorders suggest that increases in serum intact
parathyroid hormone (iPTH) levels in lithium-treated patients may not necessarily be accompanied by a parallel
increase in the concentration of Aac. If true, patients with an isolated increase in iPTH concentration above the
reference range might be missed following current screening recommendations. Therefore, this study set out to
examine key parameters of calcium metabolism, including iPTH and 25-hydroxycholecalciferol concentrations in
patients with bipolar disorder that was or was not managed with lithium.
Methods: Sixty patients with bipolar disorder according to DSM-IV were enrolled, 30 of whom had received long-
term lithium treatment (lithium group), whereas the other 30 patients were on psychopharmacological treatment
not including lithium (non-lithium group) at the time of the study. Owing to exclusion criteria (e.g., lithium < 6
months, laboratory results indicative of secondary hyperparathyroidism), 23 bipolar patients composed the final
lithium group, whereas 28 patients remained in the non-lithium group for statistical analyses.
Results: Patients in the lithium group showed a significantly higher concentration of iPTH compared to the non-
lithium group (p < 0.05). Similarly, Aac concentrations were significantly increased in the lithium group compared
to the non-lithium group (p < 0.05). However, in a multivariate linear regression model, group affiliation only
predicted iPTH concentration (p < 0.05). In line with this, none of the four patients in the lithium group with an
iPTH concentration above the reference range had an Aac concentration above the reference range.
Discussion: This study suggests that the biochemical characteristics between primary hyperparathyroidism and
lithium-induced hyperparathyroidism differ substantially with regard to regulation of calcium homeostasis. As such,
current screening practice does not reliably detect iPTH concentrations above the reference range. Therefore,
further research is needed to elucidate the consequences of an isolated iPTH concentration above the reference
range in order to develop the most appropriate screening tools for hyperparathyroidism in lithium-treated patients
with bipolar disorder.
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Lithium is one of the most widely used and most effica-
cious drugs in the different treatment phases of bipolar
disorders (Severus et al. 2012). In particular, recent data
clearly support lithium as the first-line treatment in
long-term treatment of this disorder (Weisler et al. 2011;
Geddes et al. 2010; Kessing et al. 2011). However, lith-
ium is also known to be associated with a variety of side
effects including weight gain, hypothyroidism, and
nephrogenic diabetes insipidus (Livingstone and Rampes
2006). Furthermore, lithium is listed as one of the causes
of primary hyperparathyroidism, a biochemical syn-
drome characterized by increased secretion of parathy-
roid hormone (PTH) from one or more of the parathyroid
glands (Sitges-Serra and Bergenfelz 2007; Broome and
Solorzano 2011). Most cases are sporadic in nature and
caused by a single adenoma (85%–95%) or multiglandular
disease (5%–10%) (Sitges-Serra and Bergenfelz 2007). In
case of lithium treatment, a decrease in parathyroid sensi-
tivity to calcium has been suggested as the principal
mechanism of action for the increased secretion of para-
thyroid hormone resulting in hypercalcemia, the biochem-
ical hallmark of primary hyperparathyroidism (Haden et al.
1997). Consequently, monitoring calcium levels before ini-
tiating lithium therapy and every 6 months thereafter has
been suggested as the primary screening parameter for
lithium-induced hyperparathyroidism (Livingstone and
Rampes 2006; Broome and Solorzano 2011). If calcium
levels are found to be elevated, measuring intact parathy-
roid hormone (iPTH) levels has been recommended as the
next step (Livingstone and Rampes 2006). According to the
‘International Group for The Study of Lithium Treated Pa-
tients’, between 10% and 42% of patients on lithium therapy
develop hypercalcemia and up to 29% develop hyperpara-
thyroidism (Schleicher and Kampf 2013). The available data
show that most of the studies conducted so far are case
control studies, and none of the studies focus exclusively
on patients with bipolar disorders in the test or control
groups (Saunders et al. 2009). In general, the number of
participants included in these studies is relatively small, and
only a few of these studies employed parathyroid test sys-
tems complying with today's quality standards (Souberbielle
et al. 2006). In addition, one of the more recent studies sug-
gests that following 6 months of lithium treatment, patients
have significantly increased parathyroid hormone concen-
trations without an increase in serum calcium levels (Mak
et al. 1998). This ‘normocalcemic’ subtype of lithium-
induced hyperparathyroidism will consequently remain
unrecognized if calcium is used as the sole and primary
screening instrument as is currently recommended. Inter-
estingly, in a community-based cohort of elderly men,
higher (and high normal) plasma PTH levels were associ-
ated with a higher risk of cardiovascular mortality in the
absence of hypercalcemia (Hagstrom et al. 2009). Missingthese cases of isolated higher parathyroid levels is of par-
ticular concern as bipolar disorder per se is associated with
an increased risk of cardiovascular mortality (Fiedorowicz
et al. 2008). Furthermore, additional studies suggest an as-
sociation between elevated parathyroid hormone levels and
cognitive deficits in the absence of hypercalcemia (Jorde
et al. 2006; Roman et al. 2005). Therefore, we set out to an-
swer the following hypotheses:
 Serum iPTH concentrations in patients with bipolar
disorders are increased when treated with lithium
compared to those patients treated with other drugs.
 Elevated iPTH concentrations above the reference
range may occur without a concomitant increase in
(albumin-adjusted) calcium levels.
Methods
Participants
Patients were recruited from the inpatient and outpatient
units of the Department of Psychiatry and Psychotherapy
of the Ludwig-Maximilians University, Munich. Study in-
clusion criteria were for patients who were (1) diagnosed
with bipolar disorder (I, II) according to Diagnostic and
Statistical Manual of Mental Disorders Fourth Edition
(DSM-IV), (2) able to give written informed consent, and
(3) between 18 and 65 years of age. In addition, for inclu-
sion in the lithium group, patients had to have undergone
lithium treatment for at least 6 months. Exclusion criteria
applied to patients who had a diagnosis of current sub-
stance abuse (with or without substance dependence),
borderline personality disorder or antisocial personality
disorder, significant medical co-morbidity (such as dia-
betes, malignancies, liver disease, renal impairment,
chronic infectious diseases, inflammatory bowel disease),
as well as blood parameters indicative of a secondary
hyperparathyroidism (reduced 25-hydroxycholecalciferol
concentrations in combination with iPTH concentrations
above the reference range).
Procedures
The study was approved by the Institutional Review
Board (IRB) of the Ludwig-Maximilians University,
Munich. Potentially eligible patients were approached by
one of the authors (MB) and informed about the study.
If patients were interested in participating in this study,
inclusion criteria and exclusion criteria were checked; if
patients were eligible, they were asked to sign a written
informed consent form. Subsequently, diagnosis was
confirmed using the structured clinical interview for
DSM-IV (Wittchen et al. 1997). In addition, socio-
demographic data, course of the illness, and medication
history were assessed by means of the Network Enroll-
ment Questionnaire as previously used by the Stanley
Foundation Bipolar Network (Suppes et al. 2001). In
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using standardized rating scales (YMRS (Young et al.
1978), HAMD (Hamilton 1967), BDI (Beck et al. 1961),
and Clinical Global Impressions Scale for Bipolar Illness
(Spearing et al. 1997)). Finally, a blood sample was drawn
12 h after the last medication intake. The blood sample
was used to determine the concentration of the following
parameters: serum lithium, iPTH, calcium, albumin-
adjusted calcium, phosphorus, 25-hydroxycholecalciferol,
albumin, creatinine, and urea.
Parathyroid hormone concentration was measure using
an electrochemiluminescence immunoassay, i.e., the Elecsys®
2010 Roche immunoassay (Roche Diagnostics, Germany)
which is a reliable, standardized, and well-validated method
of measuring iPTH (Hermsen et al. 2002; 2006).
Sample size justification
Adapted from the study by Mak et al. (1998) using a
variance analysis, we calculated a p value of <0.005 with
regard to the differences in the concentration of iPTH
after lithium administration. A t value of at least 3.62
was calculated which, in turn, allowed the determination
of the effect strength ‘Cohen's d’ settled by 0.80. For the
assessment of the difference between the two groups, a
one-sided t test of the null hypothesis H0 = μLit ≤
μcontr seemed to be suitable for our investigation. As
additional parameters for the power analysis, α = 0.05
and β = 0.8 were set. Given these calculations, a mini-
mum number of 20 patients per group was estimated.
Being more cautious in terms of the null hypothesis and
proposing a two-sided t test (H0 = μLit = μcontr), a
group strength of 26 patients was calculated. As some
patients were expected to drop out after enrollment due
to exclusion criteria in the blood results, a total of 30 pa-
tients per group were enrolled to ensure a sufficient
number of patients in the final model.
Statistical procedures
The data analysis was carried out using the statistical
program R 2.9.0 (Hornik 2012). Clinical and demo-
graphic characteristics were compared using t test and
Fishers exact test; t tests were used for metric variables.
For categorical variables such as gender, bipolar (I/II),
and rapid cycling (yes/no), Fishers exact test was
performed.
We wanted to know if (and if so, to what extent) the
parathyroid hormone concentration is affected by lithium
treatment including associations with lithium levels, lith-
ium dosage, and the duration of a lithium therapy. We
also wanted to investigate whether (and if so, to what ex-
tent) calcium metabolism is altered by treatment with lith-
ium or not. Therefore, a t test was used to compare both
groups in terms of interesting laboratory parameters such
as albumin-adjusted calcium, 25-hydroxycholecalciferol,and intact parathyroid hormone. Pearson correlation coef-
ficients and accordant test statistics with the parathyroid
hormone concentration were calculated for albumin-
adjusted calcium, age, 25-hydroxycholecalciferol, lithium
level, lithium dose, and duration of lithium therapy.
Selecting variables using Akaike's information criter-
ion, two linear regression models were created that best
explain the parathyroid hormone concentration and the
concentration of albumin-adjusted calcium. In order to
explain the response variable ‘parathyroid hormone con-
centration’ group affiliation, albumin-adjusted calcium,
25-hydroxycholecalciferol, age, and gender were inte-
grated as independent variables. For the response variable
‘albumin-adjusted calcium concentration’, parathyroid
hormone, group affiliation, vitamin D, age, and gender
were considered as potential explanatory variables.
The goodness-of-fit was based on the adjusted R2. The
average of metric variables is described as mean ± SD.
For all statistical calculations, the significance level
was set at 5% (p < 0.05).
Results
Study population
Thirty (30) patients with bipolar I/II disorder, who had
been on lithium for at least 6 months as well as 30 bipo-
lar patients without current lithium treatment were en-
rolled in the study. One patient in the lithium group and
one patient in the non-lithium group were excluded due
to suspected chronic kidney disease (serum creatinine
concentration above the reference range). In addition,
two patients in the lithium group and one patient in the
non-lithium group were excluded due to suspected sec-
ondary hyperparathyroidism (parathyroid hormone con-
centrations above the reference range in conjunction
with 25-hydroxycholecalciferol levels below the refer-
ence range). Finally, four patients in the lithium group
had to be excluded as new information emerged, indicat-
ing that they had been on lithium for less than 6 full
months. Therefore, a total of 23 patients on psychophar-
macological treatment (including lithium) and 28 pa-
tients on psychopharmacological treatment (excluding
lithium) were included in the statistical analysis.
The demographic and clinical characteristics of both
groups are shown in Table 1. The only item which dif-
fered significantly between the groups was the total
score of the 21-item HAMD scale. According to this
scale, patients in the non-lithium group (7.86 ± 5.86)
were more severely depressed than those in the lithium
group (4.61 ± 3.13) (p = 0.02).
The mean number of drugs was 2.57 ± 1.20 in the lith-
ium group, compared to 2.29 ± 1.24 in the non-lithium
group (p = 0.42). Among the patients in the lithium-
group, 13 were treated with anticonvulsants (valproic
acid, n = 2; lamotrigine, n = 9; carbamazepine, n = 1;
Table 1 Demographic and clinical variables of the study population
Total Lithium Non-lithium p value
(n = 51) (n = 23) (n = 28)
Age (years), mean ± SD 46.57 ± 9.21 48.48 ± 8.98 45 ± 9.26 0.18
Gender (male/female) 31/20 14/9 17/11 1
Bipolar (I/II) 33/18 12/11 21/7 0.14
Age at onset (years), mean ± SD 25.14 ± 11.24 24.43 ± 10.86 25.71 ± 11.71 0.69
Number depressive episodes (mean ± SD) 12.98 ± 15,79 10.55 ± 11,69 15.04 ± 18.56 0.31
Number mania/hypomania (mean ± SD) 8.87 ± 11.78 6.62 ± 9.11 10.76 ± 13.53 0.22
Number of drugs (mean ± SD) 2.41 ± 1.22 2.57 ± 1.20 2.29 ± 1.24 0.42
Rapid cycling (no/yes) 46/5 22/1 24/4 0.35
HAMD (mean ± SD) 6.39 ± 5.05 4.61 ± 3.13 7.86 ± 5.86 0.02
BDI (mean ± SD) 32 ± 8.84a 29.39 ± 5.66 33.50 ± 10.93a 0.09
YMRS (mean ± SD) 2.10 ± 2,56 2.04 ± 2,01 2.14 ± 2.98 0.88
aOne missing value. HAMD, Hamilton depression scale; BDI, Beck Depression Inventory; YMRS, Young Mania Rating Scale.
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lithium group were treated with anticonvulsants (val-
proic acid, n = 8; lamotrigine, n = 16).
Intact parathyroid hormone levels and albumin-adjusted
calcium concentrations
The mean intact parathyroid hormone concentration of
all 51 bipolar patients was 42.02 ± 16.81 pg/ml. The
mean concentration in the lithium group was 47.67 ±
18.27 pg/ml, compared to 37.38 ± 14.20 pg/ml in the
non-lithium group (p = 0. 03) (Table 2).
Four (4) out of 23 patients (17.39%) in the lithium
group showed parathyroid hormone concentrations
above the reference range (15 to 65 pg/ml) compared to
two of the 28 patients in the non-lithium group (7.14%).
In all six patients with iPTH levels above the reference
range, Aac concentrations were found within the normal
range.
The mean concentration of Aac in the lithium group
was 2.35 ± 0.10 mmol/l, compared to 2.29 ± 0.10 mmol/l
in the non-lithium group (p = 0.045). In the lithium group,
one patient showed albumin-adjusted calcium above the
reference range without an accompanying increase in
parathyroid hormone. No patient in the non-lithiumTable 2 Laboratory parameters of the study population
Lithium
(n = 23
iPTH concentration (mean ± SD) 47.67 p
range 2
Albumin-adjusted calcium concentration (mean ± SD) 2.35 m
range 2
25-hydroxycholecalciferol concentration (mean ± SD) 23.65 n
range 6group showed elevated concentrations for albumin-
adjusted calcium.
In the lithium group, no significant correlation be-
tween the levels of iPTH and Aac concentration could
be detected (correlation coefficient = −0.16, p = 0.48).
Similarly, there were no significant correlations between
iPTH and 25-hydroxycholecalciferol (correlation coeffi-
cient = 0.04, p = 0.84) or age (correlation coefficient =
0.12, p = 0.59). In the non-lithium group there was
no significant correlation between iPTH level and
Aac concentration either (correlation coefficient =
0.27, p = 0.16). In addition, there was no significant
correlation between iPTH concentrations and lithium
level (correlation coefficient = 0.03, p = 0.89), lithium
dose (correlation coefficient = 0.36, p = 0.09), or dur-
ation of lithium treatment (correlation coefficient =
0.34, p = 0.11) in the lithium group (Figure 1).
Finally, a multivariate linear regression model was
performed with ‘iPTH concentration’ being the dependent
variable, and group affiliation (lithium versus non-lithium,
respectively), age, gender, 25-hydroxycholecalciferol con-
centration, and Aac concentration being the explanatory
variables. Using a forward-backward stepwise selection,
‘group affiliation’ remained the only explanatory variableNon-lithium p value
) (n = 28)
g/ml ± 18.27 37.38 pg/ml ± 14.20 0.03
6.50 to 92 range 14.80 to 66.50
mol/l ± 0.10 2.29 mmol/l ± 0.10 0.045
.18 to 2.62 range 2.14 to 2.57
g/ml ± 9.20 24.56 ng/ml ± 7.85 0.71
.40 to 45.80 range 13.20 to 43.70
Figure 1 Duration of lithium treatment (in ascending order), iPTH concentration, and albumin-adjusted calcium levels. The data
represent every single patient in the lithium group.
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0.25, p = 0.03). The goodness-of-fit (adjusted R2) was
0.08.
Similarly, a multivariate linear regression model was
performed with ‘Aac concentration’ being the dependent
variable, and iPTH concentration, group affiliation,
25-hydroxycholecalciferol concentration, age, and gen-
der being the explanatory variables. Using forward-
backward stepwise selection only, ‘group affiliation’ emerged
as a significant factor (regression coefficient = 0.0646,
p = 0.0231). The goodness-of-fit (adjusted R2) was
0.08.
Discussion
To the best of our knowledge, this is the first study to sys-
tematically assess the role of lithium maintenance treat-
ment on calcium metabolism, including iPTH levels and
25-hydroxycholecalciferol concentrations in patients with
bipolar disorder. In our study, iPTH levels were signifi-
cantly higher in patients with bipolar disorder undergoing
psychopharmacological treatment that included lithium for
at least 6 months (lithium group) compared to patients
with bipolar disorder receiving psychopharmacological
treatment that excluded lithium (non-lithium group). In
line with this, group affiliation (lithium versus non-lithium)
was the only variable explaining iPTH concentrations. Fur-
thermore, none of our patients with iPTH concentrations
above the reference range would have been detected usingcurrent screening recommendations (Livingstone and
Rampes 2006; Saunders et al. 2009).
Our findings support the systematic review by Saunders
et al. (2009), which indicates that lithium may cause an in-
crease in serum calcium levels. Our study also supports
the results by Mak et al. (1998), which demonstrated that
patients with affective disorders on lithium therapy show
significantly elevated parathyroid hormone levels starting
at 6 months of lithium treatment and maintaining them
until the end of the study at 24 months compared to base-
line. In contrast to Mak et al. (1998), in our study, Aac
concentrations were also significantly increased in the lith-
ium group compared to the non-lithium group. However,
in the study by Mak et al. (1998), Aac concentration was
numerically highest at the end of the study period (i.e., at
24 months). In our study, the patients in the lithium group
were on lithium for an average of 157.70 ± 114.64 months.
Therefore, with increasing length of lithium intake, the hy-
percalcemic properties of iPTH may dominate and may
have contributed to this significant increase in Aac con-
centrations compared to the control group (non-lithium
treated patients) in our study. In addition, neither Aac
concentrations were increased in individuals with ele-
vated iPTH levels nor was there a positive significant
correlation between iPTH levels and Aac concentra-
tions in the lithium group, as has been shown in
lithium-independent normocalcemic or hypercalcemic
primary hyperparathyroidism (Shlapack and Rizvi
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cium levels were exclusively predicted by group affili-
ation. These findings strongly argue in favor of the
idea, as suggested by Mak et al. (1998), that lithium
may modulate the direct hypercalcemic action of iPTH
by its iPTH-independent direct actions on organs af-
fecting calcium metabolism, such as the kidney and
the bones. In the study by Mak et al. (1998), fasting
urinary calcium excretion was decreased throughout
the study period compared to the baseline. As alkaline
phosphatase was unchanged, this may hint to de-
creased bone resorption (the opposite of the expected
physiological effect of increased iPTH levels) and may
have contributed to the statistically unchanged Aac
concentrations throughout the study period. In this
context, it seems noteworthy that in a case–control
study, adjusted for psychotropic drug use, lithium
treatment was associated with a decreased risk of frac-
tures potentially pointing at bone anabolic properties
(Vestergaard et al. 2005).
In line with lithium's iPTH-independent actions on
calcium metabolism, our study suggests that measuring
Aac concentrations is an unsuitable tool to reliably de-
tect increased parathyroid hormone levels in lithium-
treated patients with bipolar disorder. This is in clear
contrast to current screening recommendations regard-
ing hyperparathyroidism in lithium-treated patients
(Livingstone and Rampes 2006; Saunders et al. 2009).
Whether the current screening practice needs to be
changed in which iPTH levels be used as primary
screening tool will depend on whether isolated iPTH
level increases have negative consequences on human
health, as some data, in particular with regard to mood
(Hoogendijk et al. 2008), cognition (Jorde et al. 2006;
Roman et al. 2005), and cardiovascular disease (Hagstrom
et al. 2009), suggest.
This study has several limitations:
The present study is a cross-sectional case–control
study examining parathyroid hormone concentrations in
patients with bipolar disorder with or without a current
mood episode, treated with an average of 2.5 different
drugs, with lithium being part of this treatment regimen
in one of the two groups. Ideally, to answer the question
whether lithium causes an increase in parathyroid hor-
mone levels in patients with bipolar disorder, a random-
ized, double-blind, placebo-controlled trial would be
needed in which euthymic patients with bipolar disorder
are either randomized to receive lithium monotherapy
or placebo. Unfortunately, in addition to economic rea-
sons, such a trial is unlikely to happen in the near future
as keeping patients with bipolar disorder stable on pla-
cebo for at least 6 months represents a true clinical chal-
lenge; the probability of relapse/recurrence within this
period of time is substantial and depriving patients frompsychopharmacological treatment indicated according to
current treatment guidelines is difficult to justify from
an ethical point of view. Alternatively, randomizing bi-
polar patients to either lithium or another approved
long-term treatment may be more feasible from a clin-
ical point of view. However, approved long-term treat-
ment options for bipolar disorder other than lithium are
either known to interact with calcium metabolism and
parathyroid hormone secretion or unknown (Kim et al.
2007; Ali et al. 2004).
In our study, no significant correlation was found be-
tween iPTH concentration and lithium level, lithium
dose, or duration of lithium treatment. This may be due
to a variety of reasons. First, this study was not powered
to answer these issues, e.g., the number of patients in
the lithium group may have been too small. Second,
while clinical practice suggests that elevated levels of cal-
cium (and iPTH) primarily seem to appear after many
years of lithium treatment, very little is known about
iPTH levels before calcium levels have been found to be
elevated on the occasion of periodical assessment be-
cause they simply were not assessed. Third, when ele-
vated levels of calcium and iPTH have emerged after
many years of lithium treatment, the treating psychia-
trists may switch the patient to another drug for prophy-
lactic treatment not associated with this type of side
effect. Therefore, only those individuals who do not de-
velop this type of side effect after many years of treat-
ment should continue on lithium and had the chance to
be part of the lithium group in our study.
The majority of patients in our lithium group took
2.57 different psychopharmacological drugs at the point
of assessment. While this number is not unusual in
today's published research samples of bipolar disorders
(Goldberg et al. 2009), this study does not address - and
therefore cannot answer - the question whether or not
the results would be the same in patients with bipolar dis-
orders fully responding to long-term lithium monother-
apy, as they tend to experience fewer side effects on
lithium than those not fully responding (Grof et al. 1993).
Given the cross-sectional design used as well as the
present sample size, we were unable to answer other im-
portant questions related to the subject of our paper,
such as the natural course of calcium levels and iPTH
concentrations during long-term lithium treatment, the
impact geography might play, and the effects of dosage
reduction on the aforementioned parameters. These is-
sues should be addressed in future studies.
In this study, we excluded patients with laboratory re-
sults indicative of secondary hyperparathyroidism (para-
thyroid hormone concentrations above the reference
range in conjunction with 25-hydroxycholecalciferol levels
below the reference range) from our analyses. However,
this is unlikely to have a major impact on the present
Berger et al. International Journal of Bipolar Disorders 2013, 1:7 Page 7 of 8
http://www.journalbipolardisorders.com/content/1/1/7results as just two patients in the lithium group and
one patient in the non-lithium group had to be ex-
cluded for this reason. Furthermore, in our final sam-
ple, 25-hydroxycholecalciferol concentrations neither
differed significantly between the groups nor did they
explain parathyroid hormone concentrations.
HAMD depression scores were significantly increased
in the non-lithium group compared to the lithium
group. This is most likely due to the fact that patients
on lithium treatment for at least 6 months were pre-
dominantly found among euthymic outpatients. While
affective symptoms are not known to have an impact on
iPTH levels; increased iPTH levels have been associated
with depression in adults in some (Hoogendijk et al.
2008; Driessen et al. 1995), but not all studies (Zhao
et al. 2010; Jaddou et al. 2012). Therefore, higher depres-
sion scores are unlikely to have contributed to the in-
crease in iPTH levels in the lithium group.
Similarly, anticonvulsants, including lamotrigine and
valproic acid, have been shown to increase parathyroid
hormone levels in patients with epilepsy (Kim et al.
2007). Therefore, the differences in parathyroid hormone
levels found in our study are unlikely to be brought
about by the higher number of patients in the non-
lithium group being on valproic acid or lamotrigine.
In our study, there was a substantial discrepancy be-
tween the severity of the depressive syndrome judging
from the HAMD and BDI, respectively. However, this
has been repeatedly reported in the literature in the
same direction as in our study and may, at least partly,
be explained by the HAMD being more sensitive to
change in psychopathology (Schneibel et al. 2012) and
personality characteristics, such as high neuroticism and
low extraversion, which may further add to this discrep-
ancy (Enns et al. 2000).
Conclusions
This study strongly suggests that patients with bipolar dis-
order who have undergone lithium treatment for 6 months
or more show an increase in iPTH and Aac concentrations
compared to psychopharmacological treatment without
lithium. In addition, in contrast to primary hyperparathyr-
oidism, screening with Aac concentrations does not allow
reliable detection of individual patients with iPTH concen-
trations above the reference range. Whether the current
screening practice needs to be changed and iPTH levels be
used as a primary screening tool will depend on whether
isolated iPTH level increases have negative consequences
on human health, as some preliminary data (in particular
with regard to mood, cognitive function, and cardiovascu-
lar disease) suggest. To better understand the conse-
quences of an isolated increase in iPTH concentration, the
impact of parathyroid lowering drugs such as cincacalcet
(Gregoor and de Jong 2007; Sloand and Shelly 2006; Honget al. 2012) or 25-hydroxycholecalciferol (if levels are sub-
optimal) (Durazo-Arvizu et al. 2010) on mood and/or cog-
nitive symptoms in lithium-treated symptomatic patients
with bipolar disorder should be studied in a randomized,
controlled fashion.
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